| Literature DB >> 4016798 |
P Caillé, J M Mondesir, J P Droz, P Kerbrat, A Goodman, J P Ducret, C Theodore, M Spielman, J Rouëssé, J L Amiel.
Abstract
Forty patients with advanced renal cell carcinoma were treated with elliptinium by a weekly infusion of 100 mg/m2. Of 38 evaluable patients, five had an objective response (13.2%). Average response duration was 8 months (range, 5-11). The major dose-limiting toxic effect was induction of antielliptinium antibodies, with the risk of intravascular hemolysis. Elliptinium has modest activity in advanced renal cell cancer and does not produce myelosuppression.Entities:
Mesh：
Substances：
Year: 1985 PMID： 4016798
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960